Boston Scientific (BSX) M&A announcement summary

Deal rationale and strategic fit

• Acquisition enables entry into high-growth segments like mechanical thrombectomy, embolization, and neurovascular, addressing the growing prevalence of vascular diseases.

• Expands access for more physicians and patients by leveraging global commercial footprint, supply chain, and relationships.

• Strong cultural alignment and shared focus on innovation, high performance, and clinical evidence.

• Penumbra brings a profitable growth profile and experienced team, operating as a standalone organization within the Cardiovascular group.

• Both companies operate from positions of strength, aiming to accelerate growth and enhance global patient access.

Financial terms and conditions

• Total consideration of $15 billion, with $374 per share in cash and stock; enterprise value cited as approximately $14.5 billion in some disclosures.

• Funded with approximately $11 billion in cash and $4 billion in stock (73% cash, 27% stock); equity issuance of about 41 million shares, fixed at signing.

• Shareholders can elect cash or stock, subject to proration; equity issuance based on 10-day VWAP ending January 13, 2026.

• Cash portion financed through cash on hand and new debt; nature of debt to be finalized before closing.

• Expected closing in 2026, subject to shareholder and regulatory approvals and customary conditions.

Synergies and expected cost savings

• Over $200 million of operating income impact from revenue synergies and cost efficiencies expected by year three.

• Revenue acceleration anticipated, especially outside the U.S., leveraging global sales force and proven offerings.

• Cost efficiencies targeted in G&A and operations, supporting long-range planning goals.

• Combination expected to deliver meaningful revenue contribution and margin enhancement.